Reuters logo
BRIEF-Denovo Biopharma receives FDA's permission to proceed a phase 3 trial with DB102 in the first line treatment of high risk DLBCL
October 24, 2017 / 10:19 AM / a month ago

BRIEF-Denovo Biopharma receives FDA's permission to proceed a phase 3 trial with DB102 in the first line treatment of high risk DLBCL

Oct 24 (Reuters) - Denovo Biopharma:

* Denovo Biopharma receives FDA’s permission to proceed a phase 3 clinical trial with DB102 (enzastaurin) in the first line treatment of high risk DLBCL Source text for Eikon:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below